Medical Journal of The Islamic Republic of Iran (MJIRI)
Iran University of Medical Sciences
Sat, Nov 23, 2024
[Archive]
Volume 35, Issue 1 (1-2021)
Med J Islam Repub Iran 2021 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mansoori M, Mirzaei A, Abdi Rad I, Mahmodlou R, Mansouri F, Saeednejad Zanjani L, et al . Upregulation of Ganglioside GD2 Synthase (GD2S), as a New Putative Cancer Stem Cell Marker in Breast Carcinomas. Med J Islam Repub Iran 2021; 35 (1) :1104-1112
URL: http://mjiri.iums.ac.ir/article-1-5637-en.html
URL: http://mjiri.iums.ac.ir/article-1-5637-en.html
Maryam Mansoori 
, Alireza Mirzaei , Isa Abdi Rad , Rahim Mahmodlou , Fatemeh Mansouri , Leili Saeednejad Zanjani , Zeynab Asadi- Lari , Zahra Madjd
, Alireza Mirzaei , Isa Abdi Rad , Rahim Mahmodlou , Fatemeh Mansouri , Leili Saeednejad Zanjani , Zeynab Asadi- Lari , Zahra Madjd
Abstract: (1363 Views)
Background: GD2 synthase (GD2S) is the key enzyme required for ganglioside GD2 synthesis. It is commonly expressed in normal tissues and various cancers. Ganglioside GD2 is identified as a breast cancer stem cells (BCSCs) marker that promotes tumorigenesis. As GD2S has been found to be a useful molecular marker in neuroblastoma and retinoblastoma tumors, we suggest that it can be considered as a suitable candidate for the detection of CSCs in breast cancer tissues.
Methods: Expression of GD2S was examined in 65 breast tumors compared to adjacent normal tissues, applying quantitative real-time PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA). The association between GD2S expression level and patients’ clinical characteristics was also assessed.
Results: Our findings showed that GD2S mRNA expression was significantly higher in breast cancer tissues in comparison to normal adjacent tissue samples (4.92-fold change, p<0.001) in advanced grades (p<0.001) and stages (p<0.001). It was also shown that GD2S protein expression was significantly higher in breast cancer tissues in comparison to normal adjacent tissues (4.86-fold change, p=0.010) in advanced grades (p=0.010), stages (p=0.005) and larger tumor size (p=0.002).
Conclusion: The current study showed that increased expression of GD2S in advanced breast cancer potentiates it as a promising tumor marker in these patients.
Methods: Expression of GD2S was examined in 65 breast tumors compared to adjacent normal tissues, applying quantitative real-time PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA). The association between GD2S expression level and patients’ clinical characteristics was also assessed.
Results: Our findings showed that GD2S mRNA expression was significantly higher in breast cancer tissues in comparison to normal adjacent tissue samples (4.92-fold change, p<0.001) in advanced grades (p<0.001) and stages (p<0.001). It was also shown that GD2S protein expression was significantly higher in breast cancer tissues in comparison to normal adjacent tissues (4.86-fold change, p=0.010) in advanced grades (p=0.010), stages (p=0.005) and larger tumor size (p=0.002).
Conclusion: The current study showed that increased expression of GD2S in advanced breast cancer potentiates it as a promising tumor marker in these patients.
Type of Study: Original Research |
Subject:
Cellular & Molecular Research
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
